AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32827042 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (3 × 1 hour/week at 80% VO2 peak for 8 weeks)
Number of subjects: 25
Study 32827042 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 25
Study 32827160 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 150 IU/kg every 12 hours for ages 1 month to <2 years
Number of subjects: 0
Study 32827160 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 125 IU/kg every 12 hours for ages ≥2 to <8 years
Number of subjects: 0
Study 32827160 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 100 IU/kg every 12 hours for ages ≥8 to <19 years
Number of subjects: 0
Study 32827219 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing saturated fat intake
Number of subjects: 56675
Study 32827353 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) combined with novel molecular-targeted agents (MTAs)
Number of subjects: 0
Study 32827353 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT)
Number of subjects: 0
Study 32827353 — intervention group
Group type: COMPARATOR
Intervention: Novel molecular-targeted agents (MTAs)
Number of subjects: 0
Study 32827595 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes clinics (T2DM)
Number of subjects: 3028
Study 32827595 — intervention group
Group type: COMPARATOR
Intervention: Primary care (T2DM)
Number of subjects: 3028
Study 32827595 — intervention group
Group type: COMPARATOR
Intervention: General population (without diabetes)
Number of subjects: 3028
Study 32827595 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes clinics (T2DM with prior CV events)
Number of subjects: 3028
Study 32827595 — intervention group
Group type: COMPARATOR
Intervention: Primary care (T2DM with prior CV events)
Number of subjects: 3028
Study 32827595 — intervention group
Group type: COMPARATOR
Intervention: General population (without diabetes with prior CV events)
Number of subjects: 3028
Study 32827724 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-Free Diet (GFD) for 4 weeks
Number of subjects: 50
Study 32828322 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized breast cancer risk report
Number of subjects: 337
Study 32828495 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotics-assisted laparoscopy
Number of subjects: 8
Study 32828741 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue-vitamin C-N-acetyl Cysteine (MCN)
Number of subjects: 25
Study 32828741 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 25
Study 32828763 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 1255
Study 32828763 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1255
Study 32828763 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 1255
Study 32828839 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC tracking
Number of subjects: 44
Study 32828839 — intervention group
Group type: EXPERIMENTAL
Intervention: Gating
Number of subjects: 44
Study 32828839 — intervention group
Group type: COMPARATOR
Intervention: No motion adaptation strategy
Number of subjects: 44
Study 32829467 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral and immunomodulator treatment
Number of subjects: 1
Study 32829481 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative modes of exercise therapy (cycling, lower-extremity resistance training, upper-arm ergometry, Nordic walking, combinations of exercise modes)
Number of subjects: 527
Study 32829481 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative modes of exercise therapy
Number of subjects: 527
Study 32830125 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior curvature (A)
Number of subjects: 1000
Study 32830125 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior curvature (B)
Number of subjects: 1000
Study 32830125 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinnest pachymetry (C)
Number of subjects: 1000
Study 32830125 — intervention group
Group type: EXPERIMENTAL
Intervention: Best distance visual acuity (D)
Number of subjects: 1000
Study 32830603 — intervention group
Group type: EXPERIMENTAL
Intervention: Force-feedback condition
Number of subjects: 36
Study 32830603 — intervention group
Group type: EXPERIMENTAL
Intervention: Posture-feedback condition
Number of subjects: 36
Study 32830626 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education classes offered in conjunction with a cost-offset community-supported agriculture (CSA) programme
Number of subjects: 96
Study 32830626 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education classes
Number of subjects: 96
Study 32830851 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion (BPD)
Number of subjects: 20
Study 32831103 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity Preference Assessment (APA)
Number of subjects: 60
Study 32831121 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating proteins in HFpEF patients
Number of subjects: 392
Study 32831121 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex differences in HFpEF
Number of subjects: 392
Study 32831183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash with LNS, Cash with SBCC, Cash with SBCC and LNS
Number of subjects: 2000
Study 32831183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash only
Number of subjects: 2000
Study 32831183 — intervention group
Group type: COMPARATOR
Intervention: Routine standard of care
Number of subjects: 2000
Study 32832143 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative clinical method
Number of subjects: 42
Study 32832143 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative photographic method
Number of subjects: 42
Study 32832208 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) training for PDS implant insertion and refill-exchange procedures
Number of subjects: 0
Study 32832208 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS 100 mg/mL with fixed 24-week refills
Number of subjects: 0
Study 32832558 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 0
Study 32832914 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography in prone position
Number of subjects: 27
Study 32833107 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal fluid instillation (FI)
Number of subjects: 387
Study 32833107 — intervention group
Group type: COMPARATOR
Intervention: No peritoneal fluid instillation (NFI)
Number of subjects: 387
Study 32833107 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) with FI
Number of subjects: 387
Study 32833107 — intervention group
Group type: COMPARATOR
Intervention: Non-negative pressure wound therapy (non-NPWT) with NFI
Number of subjects: 387
Study 32833193 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe depressive symptoms
Number of subjects: 455
Study 32833482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Number of subjects: 120
Study 32833482 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect labeling
Number of subjects: 120
Study 32833482 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational control
Number of subjects: 120
Study 32833717 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative medications
Number of subjects: 2375
Study 32833717 — intervention group
Group type: EXPERIMENTAL
Intervention: Home medications for comorbidities
Number of subjects: 2375
Study 32833717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative acetaminophen
Number of subjects: 2375
Study 32833717 — intervention group
Group type: EXPERIMENTAL
Intervention: Otolaryngologic preoperative comorbidity
Number of subjects: 2375
Study 32833717 — intervention group
Group type: EXPERIMENTAL
Intervention: Total comorbidities
Number of subjects: 2375
Study 32833717 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent upper respiratory infection
Number of subjects: 2375
Study 32833717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia induction
Number of subjects: 2375
Study 32834829 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut challenge (open-labelled)
Number of subjects: 36
Study 32835353 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study 32835719 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 0
Study 32835719 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity with Lynch syndrome
Number of subjects: 0
Study 32835719 — intervention group
Group type: COMPARATOR
Intervention: Women without obesity
Number of subjects: 0
Study 32835823 — intervention group
Group type: EXPERIMENTAL
Intervention: Curvilinear features of visual stimuli
Number of subjects: 0
Study 32835865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerene Cryotherapy Device
Number of subjects: 242
Study 32836087 — intervention group
Group type: COMPARATOR
Intervention: Electrophysiological connectivity in MDD
Number of subjects: 0
Study 32836087 — intervention group
Group type: COMPARATOR
Intervention: Low frequency power fluctuations (delta and theta)
Number of subjects: 0
Study 32836087 — intervention group
Group type: COMPARATOR
Intervention: Hub areas (left hippocampus, left anterior insula, bilateral dorsolateral prefrontal cortex)
Number of subjects: 0
Study 32838109 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase 50 mg
Number of subjects: 0
Study 32838109 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase 100 mg
Number of subjects: 0
Study 32838109 — intervention group
Group type: COMPARATOR
Intervention: Control (standard-of-care)
Number of subjects: 0
Study 32838323 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 764
Study 32838323 — intervention group
Group type: COMPARATOR
Intervention: No Tocilizumab (Control)
Number of subjects: 764
Study 32838558 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials developed based on participant concerns and misconceptions, including a frequently asked questions document and an educational video about broadly neutralizing antibodies.
Number of subjects: 0
Study 32838558 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials used during informed consent and throughout trial participation.
Number of subjects: 0
Study 32838558 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of behavioral research into clinical trials with broadly neutralizing antibodies.
Number of subjects: 0
Study 32838740 — intervention group
Group type: EXPERIMENTAL
Intervention: TaperGuard™ ETT
Number of subjects: 15388
Study 32838740 — intervention group
Group type: COMPARATOR
Intervention: Standard ETT
Number of subjects: 15388
Study 32838754 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 114
Study 32838754 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 114
Study 32838754 — intervention group
Group type: EXPERIMENTAL
Intervention: copeptin
Number of subjects: 114
Study 32838754 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 114
Study 32838772 — intervention group
Group type: EXPERIMENTAL
Intervention: YC-PEM e-PRO
Number of subjects: 139
Study 32839088 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU admission with severe acute cholangitis (SAC)
Number of subjects: 85
Study 32839088 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition
Number of subjects: 85
Study 32839088 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in SOFA score at 48 hours
Number of subjects: 85
Study 32839276 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported smartphone-based sleep measurements
Number of subjects: 366
Study 32839276 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatically generated smartphone-based sleep measurements
Number of subjects: 366
Study 32839276 — intervention group
Group type: COMPARATOR
Intervention: Smartphone-based sleep measurements in patients with BD
Number of subjects: 366
Study 32839491 — intervention group
Group type: EXPERIMENTAL
Intervention: AsiDNA 600 mg
Number of subjects: 22
Study 32839491 — intervention group
Group type: EXPERIMENTAL
Intervention: AsiDNA 900 mg
Number of subjects: 22
Study 32839491 — intervention group
Group type: EXPERIMENTAL
Intervention: AsiDNA (all doses)
Number of subjects: 22
Study 32840230 — intervention group
Group type: EXPERIMENTAL
Intervention: HUC-MSCs (23×10^6 cells)
Number of subjects: 54
Study 32840230 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone-marrow-derived mononuclear cells (BM-MNCs)
Number of subjects: 54
Study 32840472 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic signatures for diagnosing invasive lung adenocarcinoma in PSNs
Number of subjects: 0
Study 32840472 — intervention group
Group type: COMPARATOR
Intervention: Brock model
Number of subjects: 0
Study 32840472 — intervention group
Group type: COMPARATOR
Intervention: Clinical-semantic features
Number of subjects: 0
Study 32840472 — intervention group
Group type: COMPARATOR
Intervention: Volumetric models
Number of subjects: 0
Study 32840580 — intervention group
Group type: EXPERIMENTAL
Intervention: Steamed millet
Number of subjects: 9
Study 32840580 — intervention group
Group type: EXPERIMENTAL
Intervention: Stewed lentils
Number of subjects: 9
Study 32840580 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementation of steamed millet with stewed lentils
Number of subjects: 9
Study 32840580 — intervention group
Group type: COMPARATOR
Intervention: Reference diet with L-lysine intakes
Number of subjects: 9
Study 32840736 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD19 Chimeric Antigen Receptor T Cell (CAR T) Therapy
Number of subjects: 0
Study 32840872 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs
Number of subjects: 9145
Study 32841335 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment before conception (BC)
Number of subjects: 466
Study 32841335 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine treatment after conception (AC)
Number of subjects: 466
Study 32841541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib plus doxorubicin (sorafenib 400 mg twice daily and doxorubicin 60 mg/m2)
Number of subjects: 30
Study 32841541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib plus doxorubicin
Number of subjects: 30
Study 32841726 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided level of neck transection
Number of subjects: 195
Study 32841726 — intervention group
Group type: EXPERIMENTAL
Intervention: Firm pancreatic texture
Number of subjects: 195
Study 32841726 — intervention group
Group type: EXPERIMENTAL
Intervention: PD for non-pancreatic ductal adenocarcinoma histology
Number of subjects: 195
Study 32841726 — intervention group
Group type: EXPERIMENTAL
Intervention: Full neck resection with systematic transection ≥7 mm at the left side of the portal vein
Number of subjects: 195
Study 32841726 — intervention group
Group type: COMPARATOR
Intervention: CR-POPF
Number of subjects: 195
Study 32841726 — intervention group
Group type: COMPARATOR
Intervention: Clavien-Dindo ≥ 3 morbidity
Number of subjects: 195
Study 32841726 — intervention group
Group type: COMPARATOR
Intervention: Mortality rate
Number of subjects: 195
Study 32842043 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-exposed but HIV-negative children
Number of subjects: 4784
Study 32842043 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive children
Number of subjects: 4784
Study 32842043 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with Apgar scores < 7
Number of subjects: 4784
Study 32842043 — intervention group
Group type: EXPERIMENTAL
Intervention: Children not exclusively breast-fed up to 6 months of age
Number of subjects: 4784
Study 32842043 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-exposed and HIV-negative children
Number of subjects: 4784
Study 32842170 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemophilia carriers during pregnancy and postpartum
Number of subjects: 104
Study 32842170 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates of haemophilia carriers
Number of subjects: 104
Study 32842170 — intervention group
Group type: COMPARATOR
Intervention: Caesarean section
Number of subjects: 104
Study 32842170 — intervention group
Group type: COMPARATOR
Intervention: Basal factor level <0.4 IU/mL
Number of subjects: 104
Study 32842821 — intervention group
Group type: EXPERIMENTAL
Intervention: New surgical approach involving direct bilateral uterine arteries clamping below placental bed after broad ligament opening
Number of subjects: 63
Study 32842821 — intervention group
Group type: COMPARATOR
Intervention: Peripartum hysterectomy
Number of subjects: 63
Study 32842999 — intervention group
Group type: EXPERIMENTAL
Intervention: KORNERSTONE biobank and cohort study
Number of subjects: 0
Study 32843325 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 0
Study 32843333 — intervention group
Group type: EXPERIMENTAL
Intervention: ClassIntra grade I
Number of subjects: 2520
Study 32843333 — intervention group
Group type: EXPERIMENTAL
Intervention: ClassIntra grade II
Number of subjects: 2520
Study 32843333 — intervention group
Group type: EXPERIMENTAL
Intervention: ClassIntra grade III
Number of subjects: 2520
Study 32843333 — intervention group
Group type: EXPERIMENTAL
Intervention: ClassIntra grade IV
Number of subjects: 2520
Study 32843333 — intervention group
Group type: EXPERIMENTAL
Intervention: ClassIntra
Number of subjects: 2520
Study 32843333 — intervention group
Group type: COMPARATOR
Intervention: Postoperative complications assessed with Clavien-Dindo classification
Number of subjects: 2520
Study 32843333 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative adverse events assessed with ClassIntra
Number of subjects: 2520
Study 32843374 — intervention group
Group type: EXPERIMENTAL
Intervention: Living kidney donors
Number of subjects: 306
Study 32843374 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 306
Study 32843490 — intervention group
Group type: EXPERIMENTAL
Intervention: M4112 (100, 200, 400, 600, and 800 mg two times per day orally)
Number of subjects: 15
Study 32843493 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T targeting carcinoembryonic antigen (CEA) delivered via hepatic artery infusion (HAI) using Pressure-Enabled Drug Delivery (PEDD)
Number of subjects: 1
Study 32843493 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 systemically delivered by continuous intravenous infusion
Number of subjects: 1
Study 32843804 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided bilateral ESP block
Number of subjects: 70
Study 32843804 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided bilateral OSTAP block
Number of subjects: 70
Study 32843804 — intervention group
Group type: COMPARATOR
Intervention: Port site infiltration (control)
Number of subjects: 70
Study 32843994 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement and social support
Number of subjects: 934
Study 32844207 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk from obese mothers (OB)
Number of subjects: 159
Study 32844207 — intervention group
Group type: COMPARATOR
Intervention: Human milk from normal weight mothers (NW)
Number of subjects: 159
Study 32844221 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher skeletal muscle mass percentage (SM%) at midlife (1985/1986)
Number of subjects: 1354
Study 32844221 — intervention group
Group type: EXPERIMENTAL
Intervention: Body fat percentage (BF%) quartiles in 1985/1986
Number of subjects: 1354
Study 32844221 — intervention group
Group type: EXPERIMENTAL
Intervention: Being in the highest SM% quartile at midlife
Number of subjects: 1354
Study 32844221 — intervention group
Group type: EXPERIMENTAL
Intervention: Being in the highest BF% quartile at midlife
Number of subjects: 1354
Study 32844378 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg every 2 weeks plus 6-month prednisone taper
Number of subjects: 161
Study 32844378 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg every 4 weeks plus 6-month prednisone taper
Number of subjects: 161
Study 32844378 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 2 weeks plus 6-month or 12-month prednisone taper
Number of subjects: 161
Study 32844399 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (dosages ranging from 7.5 to 24 Gy)
Number of subjects: 2430
Study 32844399 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with anti-VEGF
Number of subjects: 2430
Study 32844399 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy combined with anti-VEGF
Number of subjects: 2430
Study 32844399 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy treatment
Number of subjects: 2430
Study 32844399 — intervention group
Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 2430
Study 32844399 — intervention group
Group type: COMPARATOR
Intervention: Very low-dose irradiation (1 Gy)
Number of subjects: 2430
Study 32844734 — intervention group
Group type: EXPERIMENTAL
Intervention: PLHIV
Number of subjects: 298
Study 32844734 — intervention group
Group type: COMPARATOR
Intervention: HIV-
Number of subjects: 298
Study 32845247 — intervention group
Group type: EXPERIMENTAL
Intervention: Current follow-up situation assessment
Number of subjects: 58
Study 32845247 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition readiness evaluation
Number of subjects: 58
Study 32845247 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of three different transition models
Number of subjects: 58
Study 32845475 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial coils treatment
Number of subjects: 21
Study 32845852 — intervention group
Group type: EXPERIMENTAL
Intervention: HEpiTracker app for tracking COVID-19 symptoms, daily body temperature, and health score reporting.
Number of subjects: 477
Study 32846061 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 55
Study 32846060 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 105
Study 32846062 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop system of insulin delivery
Number of subjects: 101
Study 32846062 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented insulin pump (control group)
Number of subjects: 101
Study 32847542 — intervention group
Group type: EXPERIMENTAL
Intervention: TPOAb-positive euthyroid women with a female fetus
Number of subjects: 938